[Inhibition of nocturnal acid secretion by pirenzepine (author's transl)].
The effect of 50 and 100 mg of 5,11-dihydro-11-[(4-methyl-piperazin-1-yl)acetyl]-6H-pyrido]2,3-b][1,4]benzodiazepin-6-one dihydrochloride (pirenzepine), respectively, given p.o. at 6 p.m. on nocturnal acid secretion was tested in 6 healthy volunteers. Pirenzepine showed a long-lasting antisecretory activity. The total acid output between 0 a.m. and 6 a.m. was reduced with 50 mg of pirenzepine by about 32% and with 100 mg of pirenzepine by about 41%. It is assumed that pirenzepine (100 mg at bedtime) should be tested in the prevention of relapse in chronic duodenal ulcer disease.
D001570:Benzodiazepinones / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D010890:Pirenzepine; D012636:Secretory Rate / Q000187:drug effects
D001570:Benzodiazepinones; D010276:Parasympatholytics; D010879:Piperazines; D010890:Pirenzepine
Hemmung der nächtlichen Nüchternsekretion durch Pirenzepin.